Scynexis Company Profile (NASDAQ:SCYX)

About Scynexis

Scynexis logoSCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SCYX
  • CUSIP:
Key Metrics:
  • Previous Close: $4.03
  • 50 Day Moving Average: $2.99
  • 200 Day Moving Average: $3.18
  • 52-Week Range: $1.74 - $7.69
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.06
  • P/E Growth: 0.00
  • Market Cap: $90.18M
  • Outstanding Shares: 23,424,000
  • Beta: 0.13
Profitability:
  • Net Margins: -12,239.31%
  • Return on Equity: -73.13%
  • Return on Assets: -62.60%
Debt:
  • Current Ratio: 11.67%
  • Quick Ratio: 11.67%
Additional Links:
Companies Related to Scynexis:

Analyst Ratings

Consensus Ratings for Scynexis (NASDAQ:SCYX) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.67 (239.12% upside)

Analysts' Ratings History for Scynexis (NASDAQ:SCYX)
Show:
DateFirmActionRatingPrice TargetDetails
8/17/2016GuggenheimInitiated CoverageBuy$15.00View Rating Details
8/9/2016WBB SecuritiesUpgradeSpeculative Buy -> Buy$8.00View Rating Details
8/9/2016Needham & Company LLCLower Price TargetBuy$16.00 -> $10.00View Rating Details
8/8/2016Brean CapitalReiterated RatingBuyView Rating Details
6/9/2016Canaccord GenuityReiterated RatingBuyView Rating Details
11/16/2015Royal Bank Of CanadaLower Price TargetOutperform$18.00 -> $17.00View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Scynexis (NASDAQ:SCYX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/11/2016        
8/8/2016Q216($0.52)($0.56)ViewN/AView Earnings Details
5/9/2016Q116($0.63)($0.52)ViewN/AView Earnings Details
11/13/2015Q315($0.62)($0.60)ViewN/AView Earnings Details
5/15/2015Q115($0.43)($0.75)$4.20 million$2.31 millionViewN/AView Earnings Details
3/30/2015($0.71)($0.45)ViewN/AView Earnings Details
11/13/2014($0.53)($0.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Scynexis (NASDAQ:SCYX)
Current Year EPS Consensus Estimate: $-1.89 EPS
Next Year EPS Consensus Estimate: $-1.96 EPS

Dividends

Dividend History for Scynexis (NASDAQ:SCYX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Scynexis (NASDAQ:SCYX)
Insider Ownership Percentage: 3.91%
Institutional Ownership Percentage: 60.30%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2016Patrick MachadoDirectorBuy40,000$2.94$117,600.00View SEC Filing  
6/30/2016Gonzalez David AnguloInsiderBuy36,950$2.22$82,029.00View SEC Filing  
6/24/2016Eric FrancoisCFOBuy15,000$2.39$35,850.00View SEC Filing  
6/24/2016Guy MacdonaldDirectorBuy40,000$2.39$95,600.00View SEC Filing  
6/24/2016Marco TagliettiCEOBuy100,000$2.39$239,000.00View SEC Filing  
5/25/2016Ann HanhamDirectorBuy4,225$3.64$15,379.00View SEC Filing  
5/25/2016Marco TagliettiCEOBuy5,754$3.26$18,758.04View SEC Filing  
5/24/2016Marco TagliettiCEOBuy5,500$3.37$18,535.00View SEC Filing  
5/23/2016Marco TagliettiCEOBuy7,500$3.14$23,550.00View SEC Filing  
5/19/2016Marco TagliettiCEOBuy6,000$3.07$18,420.00View SEC Filing  
11/24/2015Marco TagliettiCEOBuy22,733$6.79$154,357.07View SEC Filing  
8/31/2015Marco TagliettiCEOBuy25,000$7.82$195,500.00View SEC Filing  
8/28/2015Marco TagliettiCEOBuy2,267$7.08$16,050.36View SEC Filing  
8/26/2015Marco TagliettiCEOBuy50,000$7.07$353,500.00View SEC Filing  
5/7/2014Jean-Yves NothiasDirectorBuy50,000$10.00$500,000.00View SEC Filing  
5/7/2014Ventech Capital IiMajor ShareholderBuy28,000$10.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Scynexis (NASDAQ:SCYX)
DateHeadline
News IconStock Perspective: SCYNEXIS, Inc. (NASDAQ:SCYX) Company ... - Frisco Fastball (NASDAQ:SCYX)
friscofastball.com - September 26 at 5:16 AM
News IconPay Close Attention To These Analyst Ratings J M Smucker Co (NYSE:SJM), SCYNEXIS Inc (NASDAQ:SCYX) - The Voice Registrar (NASDAQ:SCYX)
voiceregistrar.com - September 25 at 2:01 PM
News IconCould SCYNEXIS Inc See a Reversal After This Very Strong Session? - Post News (NASDAQ:SCYX)
www.kentuckypostnews.com - September 25 at 2:01 PM
News IconConsensus Take: SCYNEXIS, Inc. (NASDAQ:SCYX) Earnings & Ratings Watch - Frisco Fastball (NASDAQ:SCYX)
friscofastball.com - September 22 at 6:53 PM
News IconAnalysts Set $16.00 Target Price for SCYNEXIS Inc (NASDAQ:SCYX) - DailyQuint (NASDAQ:SCYX)
dailyquint.com - September 21 at 11:17 AM
globenewswire.com logoSCYNEXIS, Inc. to Present at the Ladenburg Thalmann Healthcare Conference - GlobeNewswire (press release) (NASDAQ:SCYX)
globenewswire.com - September 21 at 11:17 AM
finance.yahoo.com logoSCYNEXIS, Inc. to Present at the Ladenburg Thalmann Healthcare Conference (NASDAQ:SCYX)
finance.yahoo.com - September 20 at 12:33 PM
capitalcube.com logoETF’s with exposure to SCYNEXIS, Inc. : September 19, 2016 (NASDAQ:SCYX)
www.capitalcube.com - September 19 at 11:48 AM
News IconStock Update, a Closer Look at SCYNEXIS, Inc. (NASDAQ:SCYX) - Duncan Research (NASDAQ:SCYX)
www.duncanindependent.com - September 15 at 7:20 PM
News IconWhat is the Sell-side Saying About SCYNEXIS, Inc. (NASDAQ:SCYX)? - Frisco Fastball (NASDAQ:SCYX)
friscofastball.com - September 15 at 7:20 PM
News IconStock Perspective: SCYNEXIS, Inc. (NASDAQ:SCYX) Earnings in View - Frisco Fastball (NASDAQ:SCYX)
friscofastball.com - September 15 at 10:52 AM
News IconKeen Investors Narrowing Their Focus on SCYNEXIS, Inc. (NASDAQ:SCYX) - Duncan Research (NASDAQ:SCYX)
www.duncanindependent.com - September 15 at 10:52 AM
News IconEarnings Analysis & Update for SCYNEXIS, Inc. (NASDAQ:SCYX)? - Frisco Fastball (NASDAQ:SCYX)
friscofastball.com - September 13 at 12:05 PM
finance.yahoo.com logoWill SCYNEXIS (SCYX) Continue to Surge Higher? (NASDAQ:SCYX)
finance.yahoo.com - September 9 at 11:59 AM
globenewswire.com logoSCYNEXIS, Inc. to Present at Upcoming Investor Conferences - GlobeNewswire (press release) (NASDAQ:SCYX)
globenewswire.com - September 1 at 7:11 PM
capitalcube.com logoETF’s with exposure to SCYNEXIS, Inc. : September 1, 2016 (NASDAQ:SCYX)
www.capitalcube.com - September 1 at 10:24 AM
publicnow.com logoSCYNEXIS, Inc. to Present at Upcoming Investor Conferences (NASDAQ:SCYX)
www.publicnow.com - August 31 at 12:37 PM
live-pr.com logoNew Market Research Report: Scynexis, Inc. (SCYX) - Financial and Strategic SWOT Analysis Review (NASDAQ:SCYX)
www.live-pr.com - August 26 at 6:59 PM
News IconSCYNEXIS stock gets bump from orphan drug designation (NASDAQ:SCYX)
wraltechwire.com - August 25 at 12:26 PM
streetinsider.com logoScynexis (SCYX) Announces Receipt of FDA Orphan Drug Designation for SCY-078 as Aspergillus Infections Treatment (NASDAQ:SCYX)
www.streetinsider.com - August 24 at 7:02 PM
streetinsider.com logoScynexis (SCYX) Announces Receipt of FDA Orphan Drug Designation for SCY-078 as Aspergillus Infections Treatment - StreetInsider.com (NASDAQ:SCYX)
www.streetinsider.com - August 24 at 10:25 AM
publicnow.com logoSCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections (NASDAQ:SCYX)
www.publicnow.com - August 24 at 10:25 AM
News IconSCYNEXIS, Inc.'s (SCYX): Stock in Focus - Hot Stocks Point (NASDAQ:SCYX)
www.hotstockspoint.com - August 22 at 7:14 PM
capitalcube.com logoETF’s with exposure to SCYNEXIS, Inc. : August 18, 2016 (NASDAQ:SCYX)
www.capitalcube.com - August 18 at 7:35 PM
schaeffersresearch.com logoAnalyst Upgrades: Valeant Pharmaceuticals Intl Inc, SCYNEXIS Inc, and Urban Outfitters, Inc. (NASDAQ:SCYX)
www.schaeffersresearch.com - August 17 at 10:18 AM
finance.yahoo.com logoSCYNEXIS INC Financials (NASDAQ:SCYX)
finance.yahoo.com - August 13 at 6:54 PM
capitalcube.com logoSCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:SCYX)
www.capitalcube.com - August 11 at 7:50 PM
finance.yahoo.com logoScynexis upgraded by WBB Securities (NASDAQ:SCYX)
finance.yahoo.com - August 9 at 10:34 AM
cnbc.com logoScynexis reports 2Q loss (NASDAQ:SCYX)
www.cnbc.com - August 8 at 12:07 PM
publicnow.com logoSCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update (NASDAQ:SCYX)
www.publicnow.com - August 8 at 12:07 PM
globenewswire.com logoSCYNEXIS, Inc. to Present at the Canaccord Genuity Growth Conference - GlobeNewswire (press release) (NASDAQ:SCYX)
globenewswire.com - August 5 at 7:33 PM
finance.yahoo.com logoSCYNEXIS, Inc. to Present at the Canaccord Genuity Growth Conference (NASDAQ:SCYX)
finance.yahoo.com - August 4 at 10:33 AM
finance.yahoo.com logoSCYNEXIS Oral SCY-078 Achieves Target Exposure With Favorable Safety And Tolerability in Patients with Invasive Candidiasis (NASDAQ:SCYX)
finance.yahoo.com - August 1 at 9:37 AM
publicnow.com logoSCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis (NASDAQ:SCYX)
www.publicnow.com - August 1 at 8:21 AM
finance.yahoo.com logo8:04 am Scynexis announces its Phase 2 study evaluating SCY-078 as a treatment in patients initially treated with IV echinocandin therapy for invasive Candida infections met all primary objectives (NASDAQ:SCYX)
finance.yahoo.com - August 1 at 8:04 AM
News IconInsiders Increasing Positions in: SCYNEXIS, Inc. (NASDAQ:SCYX) - Press Telegraph (NASDAQ:SCYX)
presstelegraph.com - July 21 at 7:38 PM
News IconScynexis Incorporated (NASDAQ:SCYX) Shorted Shares Increased By 87.29% - Press Telegraph (NASDAQ:SCYX)
presstelegraph.com - July 19 at 8:26 AM
News IconInvestor Watch: Volatility Recap on Shares of: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily (NASDAQ:SCYX)
www.engelwooddaily.com - July 19 at 8:26 AM
ftsenews.co.uk logoNew Broker Ratings For SCYNEXIS, Inc. (SCYX) - FTSE News (NASDAQ:SCYX)
www.ftsenews.co.uk - July 19 at 8:26 AM
News IconShares Moving Down on the Week: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily (NASDAQ:SCYX)
www.engelwooddaily.com - July 17 at 11:23 AM
fiscalstandard.com logoSCYNEXIS, Inc. (SCYX) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:SCYX)
www.fiscalstandard.com - July 17 at 11:23 AM
News IconEye on Stock Volatility for: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily (NASDAQ:SCYX)
www.engelwooddaily.com - July 15 at 12:34 PM
News IconIncreased Volatility Noted on Shares of: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily (NASDAQ:SCYX)
www.engelwooddaily.com - July 15 at 12:34 PM
fiscalstandard.com logoBroker Outlook For SCYNEXIS, Inc. (SCYX) - Fiscal Standard (NASDAQ:SCYX)
www.fiscalstandard.com - July 15 at 12:34 PM
streetinsider.com logoScynexis (SCYX) Sells Cyclophilin Inhibitor Assets to Cypralis - StreetInsider.com (NASDAQ:SCYX)
www.streetinsider.com - July 13 at 7:42 PM
News IconShare Volatility Watch for: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily (NASDAQ:SCYX)
www.engelwooddaily.com - July 13 at 7:42 PM
publicnow.com logoSCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited (NASDAQ:SCYX)
www.publicnow.com - July 13 at 8:48 AM
News IconScynexis Incorporated (NASDAQ:SCYX) Short Interest Increased By 87.29% - Engelwood Daily (NASDAQ:SCYX)
www.engelwooddaily.com - July 8 at 10:12 AM
News IconFollowing Unusual Volume for: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily (NASDAQ:SCYX)
www.engelwooddaily.com - July 8 at 10:12 AM
publicnow.com logoSCYNEXIS, Inc. to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:SCYX)
www.publicnow.com - July 6 at 9:21 AM

Social

Scynexis (NASDAQ:SCYX) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff